|2.48||-0.0800||-3.13%||Vol 268.31K||1Y Perf -11.25%|
|Sep 22nd, 2020 16:00 DELAYED|
|- -%||- -%|
|Target Price||7.00||Analyst Rating||Strong Buy 1.00|
|Potential %||182.26||Finscreener Ranking||— -|
|Insiders Trans % 3/6/12 mo.||-/-/-100||Value Ranking||— -|
|Insiders Value % 3/6/12 mo.||-/-/-100||Growth Ranking||★+ 42.24|
|Insiders Shares Cnt. % 3/6/12 mo.||-/-/-100||Income Ranking||— -|
|Market Cap||87.29M||Earnings Rating||Strong Buy|
|Price Range Ratio 52W %||72.93||Earnings Date||4th Nov 2020|
Today's Price Range
|Moving Averages:||Strong Buy|
|Mngmt Effectiveness||Value||Industry||S&P 500||US Markets|
ROE (5Y Avg)
ROE last 12 Months
ROA (5Y Avg)
ROA last 12 Months
ROC (5Y Avg)
ROC last 12 Months
Return on invested Capital Q
Return on invested Capital Y
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||4th Nov 2020|
|Estimated EPS Next Report||-0.21|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||304.10K|
|Avg. Monthly Volume||324.65K|
|Avg. Quarterly Volume||342.06K|
Idera Pharmaceuticals Inc. (NASDAQ: IDRA) stock closed at 2.48 per share at the end of the most recent trading day (a -3.13% change compared to the prior day closing price) with a volume of 268.31K shares and market capitalization of 87.29M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 36 people. Idera Pharmaceuticals Inc. CEO is Vincent J. Milano.
The one-year performance of Idera Pharmaceuticals Inc. stock is -11.25%, while year-to-date (YTD) performance is 36.26%. IDRA stock has a five-year performance of -91.93%. Its 52-week range is between 0.81 and 3.1, which gives IDRA stock a 52-week price range ratio of 72.93%
Idera Pharmaceuticals Inc. currently has a PE ratio of -, a price-to-book (PB) ratio of 1.29, a price-to-sale (PS) ratio of 41.75, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -174.64%, a ROC of -489.41% and a ROE of -518.02%. The company’s profit margin is -%, its EBITDA margin is -4 027.10%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from Idera Pharmaceuticals Inc., there were 2 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.21 for the next earnings report. Idera Pharmaceuticals Inc.’s next earnings report date is 04th Nov 2020.
The consensus rating of Wall Street analysts for Idera Pharmaceuticals Inc. is Strong Buy (1), with a target price of $7, which is +182.26% compared to the current price. The earnings rating for Idera Pharmaceuticals Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Idera Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Idera Pharmaceuticals Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 20.30, ATR14 : 0.21, CCI20 : 81.88, Chaikin Money Flow : -0.07, MACD : 0.13, Money Flow Index : 73.98, ROC : 26.53, RSI : 60.86, STOCH (14,3) : 68.24, STOCH RSI : 0.54, UO : 58.56, Williams %R : -31.76), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Idera Pharmaceuticals Inc. in the last 12-months were: Bryant D. Lim (Sold 1 603 shares of value $2 854 ), John J. Kirby (Sold 1 822 shares of value $3 244 ), Jonathan Michael Yingling (Sold 1 742 shares of value $3 101 ), Robert Fletcher (Sold 1 615 shares of value $2 875 ), Vincent J. Milano (Sold 3 006 shares of value $5 352 )
Copyright (c) 2020. All rights reserved. Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.com, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.